Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle

Sponsor

University of Nottingham (Other)

Overall Status

Completed

CT.gov ID

NCT02370745

Collaborator

(none)

Enrollment

Location

Arms

Actual Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study has two protocols the aims of which are:

To identify age-related effects of AA on incretin secretion and whether and to what extent AA exhibit a true incretin effect (gut- mediated increases in plasma insulin) in younger individuals. (Protocol 1)
To define the extra-pancreatic ''novel'', insulin independent effects of glucagon like peptide-1 (GLP-1) on postprandial muscle protein and glucose metabolism and microvascular blood flow. (Protocol 2)

Condition or Disease	Intervention/Treatment	Phase
Sarcopenia	Drug: GLP-1 Drug: Insulin Actrapid Dietary Supplement: Oral amino acids Drug: GIP Drug: Intravenous amino acids	N/A

Detailed Description

Protocol 1:

This will explore the first aim. 8 Healthy younger volunteers will be recruited to under go 3 arms cross over studies. Interventions will include oral and intravenous amino acids, in addition to intravenous GLP-1 and glucose dependent insulinotropic polypeptide (GIP).

8 older subjects also will be recruited for comparison of the response of GI hormones to amino acids oral feed between young and older men.

Therefore the total number will be recruited to perform this protocol is 16.

Post intervention in all visits, measurements will be taken for:

Insulin, Amino acids, GLP-1, GIP, Ghrelin and peptide YY (PYY).

The measurable end points for this protocol are:

Gut hormones levels in response to the 2 methods of AA delivery (I.V and oral)
Differences in gut hormones levels between young and older subjects when AA's are delivered orally

Protocol 2:

This will explore the second aim. 16 healthy older subjects will be recruited and subdivided randomly into two groups to receive either post absorptive or postprandial insulin concentrations with or without GLP-1 at physiological ranges in a cross over fashion . During acute study parameters of muscle glucose and amino acids metabolism will be tested together with muscle microvascular recruitment and macro vascular flow in the tested leg.

The measurable end points for this protocol are:

Muscle Glucose uptake, assessed by measuring 2-deoxyglucose (2-DOG) phosphate in muscle biopsies
Myofibrillar protein synthesis, assessed via muscle biopsy fractional synthesis rate (FSR)
Whole Leg Muscle Protein Synthesis, assessed via Arterial-Venous difference (AV method)
Whole Leg Muscle Protein Breakdown, assessed via AV method
Whole Leg Net Protein Balance, assessed via AV method
Muscle microvascular recruitment, assessed via microvascular contrast bubbles filling and refilling post destruction by ultrasound waves.

Study Design

Study Type:

Interventional

Actual Enrollment :

40 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Single (Participant)

Primary Purpose:

Basic Science

Official Title:

Characterizing the Incretin Effect of Amino Acids (AA) and Defining the Effect of GLP-1 on Muscle Microvascular Blood Flow and Muscle Protein and Glucose Metabolism in Older Age.

Actual Study Start Date :

Nov 1, 2014

Actual Primary Completion Date :

Mar 1, 2018

Actual Study Completion Date :

Mar 1, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Post absorptive insulin without GLP-1 Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition.	Drug: Insulin Actrapid Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1 Other Names: Actrapid
Experimental: Postabsorptive insulin with GLP-1 Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm. The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L .	Drug: GLP-1 GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion. Other Names: Incretin Drug: Insulin Actrapid Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1 Other Names: Actrapid
Experimental: Postprandial insulin without GLP-1 Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition	Drug: Insulin Actrapid Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1 Other Names: Actrapid
Experimental: Postprandial insulin with GLP-1 Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm. The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L .	Drug: GLP-1 GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion. Other Names: Incretin Drug: Insulin Actrapid Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1 Other Names: Actrapid
Experimental: Oral amino acids-Young Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms. The intervention here is: 15g of mixed essential amino acid drink.	Dietary Supplement: Oral amino acids Oral amino acids containing 15 g of amino acids Other Names: mixed EAA
Experimental: Intravenous (IV) amino acids- Young Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons. The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids	Drug: Intravenous amino acids This will aim to deliver iso equivalent amount to the amino acids administered orally Other Names: IV AA
Experimental: IV amino acids, GLP-1, GIP -Young Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons. The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion	Drug: GLP-1 GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion. Other Names: Incretin Drug: GIP This will be co infused with GLP-1 and intravenous amino acids Other Names: Incretin Drug: Intravenous amino acids This will aim to deliver iso equivalent amount to the amino acids administered orally Other Names: IV AA
Experimental: Oral amino acids- Older Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons. The intervention in this arm: 15 gram of oral mixed essential amino acid drink	Dietary Supplement: Oral amino acids Oral amino acids containing 15 g of amino acids Other Names: mixed EAA

Outcome Measures

Primary Outcome Measures

Muscle protein and glucose metabolism [12 months]
Assessed from muscle biopsies taken for measurement of protein synthesis and breakdown and glucose uptake.

Secondary Outcome Measures

Leg Microvascular blood flow [12 months]
Assessed via contrast enhanced ultrasound.
Leg Macrovascular blood flow [12 months]
Assessed via ultrasound doppler scans
Insulin secretion in response to oral and intravenous amino acids to assess their ability to exert incretin effect. [12 months]
Assessed via serial blood draws measuring insulin level at baseline and and post intervention.
Gut hormones secretion in response to amino acids in young and older people [12 months]
Assessed via serial blood draws measuring gut hormones at baseline and post intervention.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

For protocol 1: i. Aged between 18-40 or 65-75 years ii. A body mass index (BMI) >18 and <28 kg/m2
For Protocol 2: i. Age 65-75 years ii. A body mass index (BMI) >18 and <28 kg/m2

Exclusion Criteria:

For protocol 1:

A BMI < 18 or > 28 kg·m2 ii. Active cardiovascular disease: uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event iii. Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial) iv. Respiratory disease including pulmonary hypertension, chronic obstructive pulmonary disease (COPD), asthma or an forced expiratory volume in 1 minute (FEV1) less than 1.5 litre.
Metabolic disease: hyper and hypo-parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes vi. Active inflammatory bowel or renal disease vii. Malignancy viii. Recent steroid treatment (within 6 month), or hormone replacement therapy ix. Clotting dysfunction x. Musculoskeletal or neurological disorders xi. Family history of early (<55y) death from cardiovascular disease

For protocol 2:

Same as protocol 1 in addition to:

Overt muscle wasting i.e. muscle mass is more than 1 standard deviation below normal muscle or fat-free mass for age.
Taking beta-adrenergic blocking agents or non-steroidal anti-inflammatory drugs iii. Known sensitivity to SONOVUE or any other drug used in the study. iv. Subject deemed unsuitable for femoral cannulation at screening visit.